SCHEMBL7225332

SCHEMBL7225332

COc1ccc2c(c1)nc([S+]([O-])Cc1ncc(C)c(OC)c1C)n2S(=O)(=O)c1ccccc1S(=O)(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
CYP2C9 P11712 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 5/20 0.39
WDR5 P61964 3/20 0.39
HTT P42858 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
BRS3 P32247 2/20 0.39
ATP1A1 P05023 2/20 0.39
ATP1B1 P05026 2/20 0.39
ATP1A3 P13637 2/20 0.39
ATP1B2 P14415 2/20 0.39
ATP4A P20648 2/20 0.39
ATP1A2 P50993 2/20 0.39
ATP4B P51164 2/20 0.39
ATP1B3 P54709 2/20 0.39
FXYD2 P54710 2/20 0.39
ATP1A4 Q13733 2/20 0.39
KDM4E B2RXH2 1/20 0.39
DDAH1 O94760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7231880 0.94 CYP2C9 (0.42) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7223811 0.92 CYP2C9 (0.41) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7013702 0.89 CYP2C9 (0.43) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7009476 0.88 CYP2C9 (0.45) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7225202 0.88 CYP2C9 (0.39) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7231795 0.88 CYP2C9 (0.43) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL5339698 0.87 CYP2C9 (0.43) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7009636 0.87 CYP2C9 (0.44) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL5339696 0.86 CYP2C9 (0.43) KMT2ACYP2C9MEN1ALDH1A1WDR5
SCHEMBL7225976 0.86 CYP2C9 (0.37) KMT2ACYP2C9MEN1ALDH1A1WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed